Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Relapsed CBCC, CC and LPIC Lymphoma With FCM Chemotherapy Alone or in Combination With the Monoclonal Anti CD 20 Antibody Rituximab Followed by Anti-CD 20 Maintenance or Observation Only

NCT00317096 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.

NCT NCT00317096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Relapsed CBCC, CC and LPIC Lymphoma With FCM Chemotherapy Alone or in Combination With the Monoclonal Anti CD 20 Antibody Rituximab Followed by Anti-CD 20 Maintenance or Observation Only
Lead sponsor
Ludwig-Maximilians - University of Munich
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 1998
Completion date
June 30, 2021
Enrollment
319 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular, lymphoma, intermediate-grade, lymphoma, low-grade